ATE261310T1 - Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate - Google Patents

Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate

Info

Publication number
ATE261310T1
ATE261310T1 AT95927194T AT95927194T ATE261310T1 AT E261310 T1 ATE261310 T1 AT E261310T1 AT 95927194 T AT95927194 T AT 95927194T AT 95927194 T AT95927194 T AT 95927194T AT E261310 T1 ATE261310 T1 AT E261310T1
Authority
AT
Austria
Prior art keywords
antigen
polymer conjugates
derived polymers
polymers
amine derived
Prior art date
Application number
AT95927194T
Other languages
English (en)
Inventor
Richard B Greenwald
Anthony Martinez
Annapurna Pendri
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of ATE261310T1 publication Critical patent/ATE261310T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/3331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group cyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S526/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S526/936—Physiological use, e.g. pharmaceutical, veterinary, dental
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95927194T 1994-06-24 1995-06-23 Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate ATE261310T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26559394A 1994-06-24 1994-06-24
PCT/US1995/008909 WO1996000080A1 (en) 1994-06-24 1995-06-23 Non-antigenic amine derived polymers and polymer conjugates

Publications (1)

Publication Number Publication Date
ATE261310T1 true ATE261310T1 (de) 2004-03-15

Family

ID=23011092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927194T ATE261310T1 (de) 1994-06-24 1995-06-23 Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate

Country Status (8)

Country Link
US (3) US5730990A (de)
EP (1) EP0769955B1 (de)
JP (1) JPH10502401A (de)
AT (1) ATE261310T1 (de)
AU (1) AU3129895A (de)
CA (1) CA2191726A1 (de)
DE (1) DE69532674D1 (de)
WO (1) WO1996000080A1 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
DE69800640T2 (de) * 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
EP0981548A4 (de) * 1997-04-30 2005-11-23 Enzon Inc Glykosylierungsfähige einzelkettige antigen-bindende proteine, herstellung und verwendung derselben
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US20050158273A1 (en) * 1997-09-25 2005-07-21 Harris J. M. Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
DE69934890D1 (de) * 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
US20030143662A1 (en) * 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
KR20020022691A (ko) * 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1111166C (zh) * 1999-09-10 2003-06-11 云南汉德生物技术有限公司 水溶性三尖杉磷碱聚氨基酸酯或其盐,含它们的药物组合物及其医药用途
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
AU2223401A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Branched polyalkylene glycols
SK11672002A3 (sk) 2000-01-10 2002-12-03 Maxygen Holdings Ltd. Polypeptidový konjugát, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
MXPA03000311A (es) * 2000-07-12 2004-12-13 Gryphon Therapeutics Inc Produccion y uso de moduladores de receptor de quimiocina.
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EE200300089A (et) * 2000-09-08 2005-02-15 Gryphon Therapeutics, Inc. Sünteetilised erütropoeesi stimuleerivad valgud, nende valmistamismeetodid ning kasutamine
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP2080771A3 (de) 2001-02-27 2010-01-06 Maxygen Aps Neue Interferon-betaartige Moleküle
JP2004535401A (ja) 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
IL159496A0 (en) * 2001-06-22 2004-06-01 Pharmacia Corp Chemically-modified progenipoietin conjugates
US20030031677A1 (en) * 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EE05509B1 (et) * 2002-01-18 2012-02-15 Biogen@Idec@Ma@Inc Aktiveeritud polalkleenglkoolpolmeer ja seda sisaldavad kompositsioonid
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
RU2362807C2 (ru) 2002-06-21 2009-07-27 Ново Нордиск Хелт Кэр Аг Конъюгат полипептида фактора vii, способ его получения, его применение и содержащая его фармацевтическая композиция
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
NZ541122A (en) * 2002-12-26 2008-09-26 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8034900B2 (en) * 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2633866A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
EP2327724A3 (de) 2004-02-02 2011-07-27 Ambrx, Inc. Modifizierte humane Wachstumshormon-Polypeptide und deren Verwendungen
US6887952B1 (en) 2004-02-12 2005-05-03 Biosite, Inc. N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
MXPA06010782A (es) * 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
WO2006031583A2 (en) * 2004-09-09 2006-03-23 Biosite Incorporated Methods and compositions for measuring canine bnp and uses thereof
CN102732588B (zh) 2004-12-22 2015-01-07 Ambrx公司 氨酰基-tRNA合成酶的组合物及其用途
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
JP2008525473A (ja) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
WO2006078813A2 (en) * 2005-01-21 2006-07-27 Biosite Incorporated Arginine analogs, and methods for their synthesis and use
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
CA2602654A1 (en) 2005-04-05 2006-10-12 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for shielding functional sites or epitopes on proteins
TWI264608B (en) * 2005-04-08 2006-10-21 Delta Electronics Inc Light tunnel module
WO2006133089A2 (en) 2005-06-03 2006-12-14 Ambrx, Inc. Improved human interferon molecules and their uses
EP1893632B1 (de) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
EP1951890A4 (de) 2005-11-16 2009-06-24 Ambrx Inc Verfahren und zusammensetzungen mit nichtnatürlichen aminosäuren
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
KR101513732B1 (ko) 2006-02-21 2015-04-21 넥타르 테라퓨틱스 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (de) 2006-05-02 2012-05-09 Allozyne, Inc. Aminosäuresubstituierte Moleküle
KR20090013816A (ko) 2006-05-24 2009-02-05 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체
MX2009002460A (es) 2006-09-08 2009-03-20 Ambrx Inc Arnt supresor hibrido para celulas de vertebrados.
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2064333B1 (de) 2006-09-08 2014-02-26 Ambrx, Inc. Unterdrücker-trna-transkription für wirbeltierzellen
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
WO2008098178A2 (en) * 2007-02-09 2008-08-14 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
EP2147122B1 (de) * 2007-04-20 2014-07-16 Sigma-Tau Rare Diseases S.A. Enzymatische tumortherapie
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
JP5868594B2 (ja) * 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
PE20110480A1 (es) 2008-09-26 2011-07-01 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
WO2010104883A1 (en) * 2009-03-09 2010-09-16 Molecular Express, Inc. Methods and compositions for liposomal formulation of antigens and uses thereof
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
EP2569331A1 (de) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptid-inhibitoren von vla4
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
US9422338B2 (en) 2011-05-19 2016-08-23 Epodose Llc Compounds that bind to the erythropoietin receptor
FI3461807T3 (fi) 2011-06-08 2023-09-07 Life Technologies Corp Uudenlaisten detergenttien suunnittelu ja kehitys pcr-järjestelmissä käyttöä varten
WO2012170907A2 (en) 2011-06-08 2012-12-13 Life Technologies Corporation Polymerization of nucleic acids using proteins having low isoelectric points
EP2726502A1 (de) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin-fusionspolypeptide und ihre verwendung
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
EP2970319A4 (de) 2013-03-14 2016-11-09 Alere San Diego Inc 6-acetylmorphin-analoga und verfahren zu deren synthese und verwendung
JP6358661B2 (ja) * 2013-03-19 2018-07-18 公立大学法人首都大学東京 界面活性剤様化合物
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
EP3539944A1 (de) 2013-10-25 2019-09-18 Life Technologies Corporation Neuartige verbindungen zur verwendung in pcr-systemen und anwendungen davon
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
EP3373922B1 (de) 2015-11-09 2022-01-05 The Regents of The University of Colorado, A Body Corporate Zusammensetzungen und verfahren zur verwendung zur behandlung von homocystinurie
EP4610656A3 (de) 2016-04-15 2025-11-19 Beckman Coulter, Inc. Photoaktive makromoleküle und ihre verwendung
EP3458439B1 (de) 2016-05-18 2021-12-08 Alere San Diego, Inc. 2-ethyliden-1,5-dimethyl-3,3-diphenylpyrrolidin-analoga sowie methoden zu deren synthese und verwendung
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
KR20230159629A (ko) 2016-12-12 2023-11-21 벡톤 디킨슨 앤드 컴퍼니 수용성 중합체 염료
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
TWI911136B (zh) 2017-03-29 2026-01-11 開曼群島商北極星藥業集團股份有限公司 蛋白質結合物
EP3612214A4 (de) 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate Optimierung der enzymersatztherapie zur behandlung von homocystinurie
AU2018283973B2 (en) 2017-06-11 2025-04-24 Molecular Express, Inc. Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
CN119286279A (zh) 2017-12-26 2025-01-10 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
CN119220109A (zh) 2018-03-30 2024-12-31 贝克顿·迪金森公司 含侧基发色团的水溶性聚合染料
US20220162336A1 (en) 2018-07-22 2022-05-26 Bioasis Technologies, Inc. Treatment of lymphatic metastases
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4143227A2 (de) 2020-04-30 2023-03-08 Sairopa B.V. Anti-cd103 antikörper
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
EP4199968A1 (de) 2020-08-20 2023-06-28 Ambrx, Inc. Antikörper-tlr-agonist-konjugate, verfahren und verwendungen davon
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
US20250161471A1 (en) 2021-04-03 2025-05-22 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4547759A2 (de) 2022-07-01 2025-05-07 Beckman Coulter, Inc. Neue fluoreszenzfarbstoffe und polymere aus dihydrophenanthren-derivaten
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
CN120936679A (zh) 2023-03-17 2025-11-11 贝克曼库尔特有限公司 苯并噻吩并吡咯花菁染料
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
IT1107772B (it) * 1977-08-22 1985-11-25 Cancer Res Inst Royal Procedimento per la produzione di complessi macromolecolari prodotto ottenuto e composizioni farmaceutiche che lo contengono come ingrediente attivo
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4690916A (en) * 1984-11-13 1987-09-01 Syntex (U.S.A.) Inc. Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4680338A (en) * 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JP2795491B2 (ja) * 1988-11-16 1998-09-10 三井化学株式会社 分子末端に２級アミノ基を有するポリオキシアルキレンポリアミンを製造する方法
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8918589D0 (en) * 1989-08-15 1989-09-27 Graham Neil B Polymeric compositions
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU6400094A (en) * 1993-03-09 1994-09-26 Enzon, Inc. Taxol polyalkylene oxide conjugates of taxol and taxol intermediates
EP0632082B1 (de) * 1993-06-29 1997-04-02 "HEYLECINA", Société Anonyme Herstellung von aktivierten Carbamaten von Polyalkylenglycol und ihre Verwendung
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates

Also Published As

Publication number Publication date
US6177087B1 (en) 2001-01-23
CA2191726A1 (en) 1996-01-04
AU3129895A (en) 1996-01-19
DE69532674D1 (de) 2004-04-15
US5730990A (en) 1998-03-24
US5902588A (en) 1999-05-11
EP0769955B1 (de) 2004-03-10
EP0769955A1 (de) 1997-05-02
EP0769955A4 (de) 1997-11-05
WO1996000080A1 (en) 1996-01-04
JPH10502401A (ja) 1998-03-03

Similar Documents

Publication Publication Date Title
ATE261310T1 (de) Nicht-antigene von aminen abgeleitete polymere und polymerkonjugate
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
EP1019365A4 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
NO964632L (no) Gjennvinnbare plastfilmer
PL327454A1 (en) Implantable hydrogel of an acrylamide polymer for therapeutic purposes
PT853627E (pt) Lipossacaridos substituidos uteis no tratamento e prevencao de endotoxemia
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE231891T1 (de) Supramolekular polymere
DE69828067D1 (de) Kationische polymere zur bindung von toxinen
ATE213005T1 (de) Kontinuierliches polymerisationverfahren von polyamiden
ATE244404T1 (de) Zusammensetzungen und verfahren zur hemmung der licht-induzierten inaktivierung von biologischen reagenzien
DE50001509D1 (de) Carboxylfunktionelles additiv zur aufkondensierung von polyamiden
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
AU8040898A (en) Type-1 ribosome-inactivating protein
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
DE59915171D1 (de) Modifiziertes polymer und modifizierte polymermembran
ATE286940T1 (de) Verfahren und vorrichtung zum kontinuierlichen herstellen eines thermoplastischen polymerblends und dessen verwendung
SE8403075D0 (sv) Polyamidoaminepolyamines
AR001732A1 (es) Celulasa alcalina novedosa y método para producirla
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
DE69507067D1 (de) Verfahren zur Herstellung von hochmolekularen Acrylamidpolymeren
SE9802507D0 (sv) Novel salts
DE59504450D1 (de) Neue tetrapeptide, ihre herstellung und verwendung
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
ATE165381T1 (de) Kondensations- und additionspolymere mit n,n'- verbrückten bis-tetramethylpiperidinyloxy- gruppierungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties